We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
Read MoreHide Full Article
Key Takeaways
AbbVie raises 2026 revenue guidance to $67.8B and adjusted EPS outlook to $13.95-$13.99 on strong demand.
Skyrizi and Rinvoq sales grew 22.9% and 24.3%, respectively, driving higher full-year immunology forecasts.
ABBV's oncology pipeline advances as etentamig targets a 2027 decision and Epkinly shows promising results.
AbbVie Inc. (ABBV - Free Report) raised its 2026 guidance during its third-quarter earnings call, citing sustained demand for its immunology and neuroscience treatments. Management emphasized continued growth from Skyrizi and Rinvoq, alongside expanding opportunities across its development pipeline.
The discussion also addressed competitive pressures, drug pricing, regulatory milestones and commercialization timelines that could influence growth through 2027 and beyond.
ABBV Raises 2026 Outlook on Stronger Demand
Chairman and CEO Robert Michael highlighted broad-based commercial momentum, supporting another upward revision to annual guidance. AbbVie now expects approximately $67.8 billion in 2026 revenues, an increase of $200 million.
CFO Scott Reents raised adjusted earnings guidance to $13.95-$13.99 per share, with fourth-quarter revenues projected at approximately $18.4 billion and adjusted earnings of $3.83-$3.87 per share.
Third-quarter adjusted earnings reached $3.82 per share, exceeding the Zacks Consensus Estimate of $3.74. Revenues of $17.4 billion surpassed the Zacks Consensus Estimate of $17.37 billion, increasing 10.3% year over year.
Rinvoq generated $2.706 billion, increasing 24.3% operationally. Management raised full-year sales forecasts for both products to $21.8 billion and $10.3 billion, respectively.
During questioning from JPMorgan, Stewart explained that newly approved subcutaneous Skyrizi induction for Crohn's disease could accelerate patient-share gains beginning in early 2027. Full payer access should take approximately 60 days or longer.
ABBV Targets Additional Neuroscience Growth
Stewart highlighted continued demand across neuroscience, where quarterly revenues reached $3.389 billion, growing 19.5% operationally. Vraylar, Ubrelvy and Qulipta contributed to this expansion.
The FDA approval of Juvmo adds another Parkinson's treatment to AbbVie's portfolio. Management expects broader Medicare coverage beginning in 2028, delaying a more significant commercial ramp.
Responding to Wells Fargo, Stewart described encouraging initial physician interest in Juvmo but acknowledged near-term reimbursement limitations. Michael also identified upcoming Medicare drug-pricing changes for Vraylar as a 2027 headwind.
Chief scientific officer Roopal Thakkar highlighted positive Phase III results for etentamig in multiple myeloma. AbbVie submitted its U.S. regulatory application and anticipates an approval decision in 2027.
Epkinly also demonstrated encouraging results in frontline diffuse large B-cell lymphoma, reducing the risk of disease progression or death by 51% when combined with R-CHOP.
During JPMorgan and other analyst discussions, management emphasized the commercial potential of these programs. Stewart expects rapid adoption of Epkinly's frontline indication following approval, supported by its combination with an established treatment regimen.
ABBV Addresses Pricing and Development Risks
During questioning from TD Cowen, Michael addressed the dispute concerning Botox eligibility for Medicare drug-price negotiations. He cited a favorable federal district court ruling while acknowledging the government's ability to appeal.
Thakkar also discussed uncertainties surrounding Rinvoq's upcoming hidradenitis suppurativa trial results. She emphasized pain reduction, disease flares and quality-of-life improvements alongside clinical response rates.
Meanwhile, aesthetics revenues declined 1.8% operationally. Stewart cited continued dermal filler weakness, although improving Botox Cosmetic demand provided some support.
AbbVie Prioritizes Pipeline Depth and Cash Returns
Michael characterized future acquisitions as predominantly bolt-on transactions following the completed Apogee Therapeutics acquisition. Immunology, neuroscience, oncology and obesity remain priority areas.
Reents reported approximately $14 billion in free cash flow during the first nine months, supporting continued investment and shareholder distributions.
Management increased the quarterly dividend 5.2% to $1.82 per share, effective with the February 2027 payment, while maintaining its focus on sustained portfolio expansion.
ABBV's Zacks Rank and Style Scores Signal Caution
ABBV currently carries a Zacks Rank #4 (Sell), indicating an unfavorable earnings-estimate revision outlook. Its Value Score of D and Momentum Score of F indicate weak relative characteristics in these investment styles.
The Growth Score of B reflects more favorable growth attributes, but the combined VGM Score of D points to limited overall style attractiveness. The Zacks Rank could change as analysts revise earnings estimates following the newly reported results.
View the Zacks #1 Rank List
Image: Bigstock
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
Key Takeaways
AbbVie Inc. (ABBV - Free Report) raised its 2026 guidance during its third-quarter earnings call, citing sustained demand for its immunology and neuroscience treatments. Management emphasized continued growth from Skyrizi and Rinvoq, alongside expanding opportunities across its development pipeline.
The discussion also addressed competitive pressures, drug pricing, regulatory milestones and commercialization timelines that could influence growth through 2027 and beyond.
ABBV Raises 2026 Outlook on Stronger Demand
Chairman and CEO Robert Michael highlighted broad-based commercial momentum, supporting another upward revision to annual guidance. AbbVie now expects approximately $67.8 billion in 2026 revenues, an increase of $200 million.
CFO Scott Reents raised adjusted earnings guidance to $13.95-$13.99 per share, with fourth-quarter revenues projected at approximately $18.4 billion and adjusted earnings of $3.83-$3.87 per share.
Third-quarter adjusted earnings reached $3.82 per share, exceeding the Zacks Consensus Estimate of $3.74. Revenues of $17.4 billion surpassed the Zacks Consensus Estimate of $17.37 billion, increasing 10.3% year over year.
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. price-consensus-eps-surprise-chart | AbbVie Inc. Quote
AbbVie's Immunology Franchise Remains Central
Chief commercial officer Jeffrey Stewart emphasized Skyrizi's sustained market penetration despite increasing competition. Quarterly sales reached $5.776 billion, representing 22.9% operational growth.
Rinvoq generated $2.706 billion, increasing 24.3% operationally. Management raised full-year sales forecasts for both products to $21.8 billion and $10.3 billion, respectively.
During questioning from JPMorgan, Stewart explained that newly approved subcutaneous Skyrizi induction for Crohn's disease could accelerate patient-share gains beginning in early 2027. Full payer access should take approximately 60 days or longer.
ABBV Targets Additional Neuroscience Growth
Stewart highlighted continued demand across neuroscience, where quarterly revenues reached $3.389 billion, growing 19.5% operationally. Vraylar, Ubrelvy and Qulipta contributed to this expansion.
The FDA approval of Juvmo adds another Parkinson's treatment to AbbVie's portfolio. Management expects broader Medicare coverage beginning in 2028, delaying a more significant commercial ramp.
Responding to Wells Fargo, Stewart described encouraging initial physician interest in Juvmo but acknowledged near-term reimbursement limitations. Michael also identified upcoming Medicare drug-pricing changes for Vraylar as a 2027 headwind.
AbbVie's Oncology Pipeline Approaches Key Milestones
Chief scientific officer Roopal Thakkar highlighted positive Phase III results for etentamig in multiple myeloma. AbbVie submitted its U.S. regulatory application and anticipates an approval decision in 2027.
Epkinly also demonstrated encouraging results in frontline diffuse large B-cell lymphoma, reducing the risk of disease progression or death by 51% when combined with R-CHOP.
During JPMorgan and other analyst discussions, management emphasized the commercial potential of these programs. Stewart expects rapid adoption of Epkinly's frontline indication following approval, supported by its combination with an established treatment regimen.
ABBV Addresses Pricing and Development Risks
During questioning from TD Cowen, Michael addressed the dispute concerning Botox eligibility for Medicare drug-price negotiations. He cited a favorable federal district court ruling while acknowledging the government's ability to appeal.
Thakkar also discussed uncertainties surrounding Rinvoq's upcoming hidradenitis suppurativa trial results. She emphasized pain reduction, disease flares and quality-of-life improvements alongside clinical response rates.
Meanwhile, aesthetics revenues declined 1.8% operationally. Stewart cited continued dermal filler weakness, although improving Botox Cosmetic demand provided some support.
AbbVie Prioritizes Pipeline Depth and Cash Returns
Michael characterized future acquisitions as predominantly bolt-on transactions following the completed Apogee Therapeutics acquisition. Immunology, neuroscience, oncology and obesity remain priority areas.
Reents reported approximately $14 billion in free cash flow during the first nine months, supporting continued investment and shareholder distributions.
Management increased the quarterly dividend 5.2% to $1.82 per share, effective with the February 2027 payment, while maintaining its focus on sustained portfolio expansion.
ABBV's Zacks Rank and Style Scores Signal Caution
ABBV currently carries a Zacks Rank #4 (Sell), indicating an unfavorable earnings-estimate revision outlook. Its Value Score of D and Momentum Score of F indicate weak relative characteristics in these investment styles.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Growth Score of B reflects more favorable growth attributes, but the combined VGM Score of D points to limited overall style attractiveness. The Zacks Rank could change as analysts revise earnings estimates following the newly reported results.